Quantum BioPharma is trading 5.86% up at $3.90 after its August 17, 2026 second-quarter update reported a 53% year-over-year reduction in operating expenses and approximately $9.5 million in liquidity.

  • The company reiterated progress toward a Phase 2 Lucid-MS trial following FDA clearance.
  • Broader markets are weaker, suggesting company-specific interest is outweighing risk-off sentiment.
  • No separate August 18, 2026 announcement was identified; the pre-market move appears linked to the recent results and development update.